Global Neuropsychiatric Disorders And Treatment Market

Neuropsychiatric Disorders And Treatment Comprehensive Study by Types (Degenerative Diseases, Psychosis, Neurotic Disorder), End Users (Hospitals, Specialty Clinics, Research & Development Centers, Academic Institutions, Others), Route of Administration (Oral, Parenteral), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others), Treatments (Shock Treatments, Drug Treatments, Others), Drug Class (Cholinesterase Inhibitors, NMDA Receptor Antagonists, Antiepileptic, Antipsychotic, Antidepressant, Others) Players and Region - Global Market Outlook to 2028

Neuropsychiatric Disorders And Treatment Market by XX Submarkets | Forecast Years 2023-2028 | CAGR: 7.3%  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Neuropsychiatric Disorders And Treatment
Neuropsychiatric disorder is a medical term where a set of mental illness related to brain functioning and behavior. They includes such as dementia, Alzheimer's disease, Parkinson's disease, Huntington's disease, attention deficit hyperactivity disorder, schizophrenia and bipolar disease. The treatment of neuropsychiatric disorders often requires a multidisciplinary approach involving collaboration among neurologists, psychiatrists, geriatricians, neuropsychologists, and other healthcare professionals. Additionally, integrated approaches combining pharmacotherapy, psychotherapy, and surgical interventions may be necessary for managing complex neuropsychiatric cases effectively. The Neuropsychiatric Disease and Treatment journal publishes clinical or pre-clinical studies on a range of neuropsychiatric and neurological disorders, focusing on concise rapid reporting of research in this field. The growth of this market can advance the neuroscience.

AttributesDetails
Study Period2018-2028
Base Year2022
UnitValue (USD Million)
CAGR7.3%


The neurological disorder drugs market provide overview, company financials, revenue generators, market potencies, investment in Research and developments, new market initiatives, global presence and product launch. The data only provides neurological disorder market. Analyst at AMA Research estimates that United States Players will contribute the maximum growth to Global Neuropsychiatric Disorders And Treatment market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

AviadoBio (United Kingdom), Universal Health Services Inc (United States), Bristol-Meyer Squibb (United States), Wyeth (United States), Eli Lilly (United States), Biogen (Unites States), Astrazeneca (United Kingdom), Glaxosmithkline (United Kingdom) and Alto Neuroscience, Inc. (United States) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Johnson & Johnson (United States), Pfizer (United States), Otsuka Holdings Co. Ltd (Japan), Astellas Pharma Inc. (Japan) and Boehringer ingelheim Gmbh (Germany).

Segmentation Overview
AMA Research has segmented the market of Global Neuropsychiatric Disorders And Treatment market by and Region.



On the basis of geography, the market of Neuropsychiatric Disorders And Treatment has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Types, the sub-segment i.e. Degenerative Diseases will boost the Neuropsychiatric Disorders And Treatment market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by End Users, the sub-segment i.e. Hospitals will boost the Neuropsychiatric Disorders And Treatment market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Route of Administration, the sub-segment i.e. Oral will boost the Neuropsychiatric Disorders And Treatment market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Distribution Channel, the sub-segment i.e. Hospital Pharmacy will boost the Neuropsychiatric Disorders And Treatment market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Treatments, the sub-segment i.e. Shock Treatments will boost the Neuropsychiatric Disorders And Treatment market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Drug Class, the sub-segment i.e. Cholinesterase Inhibitors will boost the Neuropsychiatric Disorders And Treatment market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Increasing use of digital tools, mobile applications, and telehealth for assessment, monitoring, and intervention in neuropsychiatric disorders and Growing interest in precision medicine and personalized treatment plans based on individual genetic, neurobiological, and environmental factors

Market Growth Drivers:
Growing heavy population in market growth, Advancements in Neuroscience and Increasing investments of healthcare infrastructures

Challenges:
Treatment gap due to limited resources, inadequate workforce, and systemic barriers

Restraints:
Lack of healthcare infrastructure in developing economies and shortage of skilled professionals

Opportunities:
The growing field of digital mental health and Development of New Drugs

Market Leaders and their expansionary development strategies
In October 2023, Sosei Group Corporation and PharmEnable had collaborate o drive novel drug discovery for a second neurological disease target. Sosei's expertise in structure-based drug design (SBDD) for receptor protein structure determination and translational development and PharmEnable's proprietary artificial intelligence (AI)-enabled medicinal chemistry platform, chem UNIVERSE, for designing highly specific drug leads for further development
In September 2023, Arialys Therapeutics had launched medicines for autoimmune Neuropsychiatric diseases the aim was to block pathogenic autoantibodies in the brain to expand treatment possibilities for neuropsychiatric disorders driven by autoimmune disease and develops an antibody therapeutic, ART5803, to treat anti-NMDA receptor encephalitis (ANRE), a form of autoimmune encephalitis caused by crosslinking autoantibodies that drive internalization of NMDA receptors, resulting in seizures and psychosis in patients


Key Target Audience
Patients and Caregivers, Healthcare Professionals, Mental Health Practitioners, Research and Academics, Technology developers and Pharmaceutical and Biotech Companies

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Types
  • Degenerative Diseases
  • Psychosis
  • Neurotic Disorder

By End Users
  • Hospitals
  • Specialty Clinics
  • Research & Development Centers
  • Academic Institutions
  • Others

By Route of Administration
  • Oral
  • Parenteral

By Distribution Channel
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • Others

By Treatments
  • Shock Treatments
  • Drug Treatments
  • Others

By Drug Class
  • Cholinesterase Inhibitors
  • NMDA Receptor Antagonists
  • Antiepileptic
  • Antipsychotic
  • Antidepressant
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Growing heavy population in market growth
      • 3.2.2. Advancements in Neuroscience
      • 3.2.3. Increasing investments of healthcare infrastructures
    • 3.3. Market Challenges
      • 3.3.1. Treatment gap due to limited resources, inadequate workforce, and systemic barriers
    • 3.4. Market Trends
      • 3.4.1. Increasing use of digital tools, mobile applications, and telehealth for assessment, monitoring, and intervention in neuropsychiatric disorders
      • 3.4.2. Growing interest in precision medicine and personalized treatment plans based on individual genetic, neurobiological, and environmental factors
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Neuropsychiatric Disorders And Treatment, by Types, End Users, Route of Administration, Distribution Channel, Treatments, Drug Class and Region (value) (2017-2022)
    • 5.1. Introduction
    • 5.2. Global Neuropsychiatric Disorders And Treatment (Value)
      • 5.2.1. Global Neuropsychiatric Disorders And Treatment by: Types (Value)
        • 5.2.1.1. Degenerative Diseases
        • 5.2.1.2. Psychosis
        • 5.2.1.3. Neurotic Disorder
      • 5.2.2. Global Neuropsychiatric Disorders And Treatment by: End Users (Value)
        • 5.2.2.1. Hospitals
        • 5.2.2.2. Specialty Clinics
        • 5.2.2.3. Research & Development Centers
        • 5.2.2.4. Academic Institutions
        • 5.2.2.5. Others
      • 5.2.3. Global Neuropsychiatric Disorders And Treatment by: Route of Administration (Value)
        • 5.2.3.1. Oral
        • 5.2.3.2. Parenteral
      • 5.2.4. Global Neuropsychiatric Disorders And Treatment by: Distribution Channel (Value)
        • 5.2.4.1. Hospital Pharmacy
        • 5.2.4.2. Retail Pharmacy
        • 5.2.4.3. Online Pharmacy
        • 5.2.4.4. Others
      • 5.2.5. Global Neuropsychiatric Disorders And Treatment by: Treatments (Value)
        • 5.2.5.1. Shock Treatments
        • 5.2.5.2. Drug Treatments
        • 5.2.5.3. Others
      • 5.2.6. Global Neuropsychiatric Disorders And Treatment by: Drug Class (Value)
        • 5.2.6.1. Cholinesterase Inhibitors
        • 5.2.6.2. NMDA Receptor Antagonists
        • 5.2.6.3. Antiepileptic
        • 5.2.6.4. Antipsychotic
        • 5.2.6.5. Antidepressant
        • 5.2.6.6. Others
      • 5.2.7. Global Neuropsychiatric Disorders And Treatment Region
        • 5.2.7.1. South America
          • 5.2.7.1.1. Brazil
          • 5.2.7.1.2. Argentina
          • 5.2.7.1.3. Rest of South America
        • 5.2.7.2. Asia Pacific
          • 5.2.7.2.1. China
          • 5.2.7.2.2. Japan
          • 5.2.7.2.3. India
          • 5.2.7.2.4. South Korea
          • 5.2.7.2.5. Taiwan
          • 5.2.7.2.6. Australia
          • 5.2.7.2.7. Rest of Asia-Pacific
        • 5.2.7.3. Europe
          • 5.2.7.3.1. Germany
          • 5.2.7.3.2. France
          • 5.2.7.3.3. Italy
          • 5.2.7.3.4. United Kingdom
          • 5.2.7.3.5. Netherlands
          • 5.2.7.3.6. Rest of Europe
        • 5.2.7.4. MEA
          • 5.2.7.4.1. Middle East
          • 5.2.7.4.2. Africa
        • 5.2.7.5. North America
          • 5.2.7.5.1. United States
          • 5.2.7.5.2. Canada
          • 5.2.7.5.3. Mexico
  • 6. Neuropsychiatric Disorders And Treatment: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2022)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. AviadoBio (United Kingdom)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Universal Health Services Inc (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Bristol-Meyer Squibb (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Wyeth (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Eli Lilly (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Biogen (Unites States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Astrazeneca (United Kingdom)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Glaxosmithkline (United Kingdom)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Alto Neuroscience, Inc. (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
  • 7. Global Neuropsychiatric Disorders And Treatment Sale, by Types, End Users, Route of Administration, Distribution Channel, Treatments, Drug Class and Region (value) (2023-2028)
    • 7.1. Introduction
    • 7.2. Global Neuropsychiatric Disorders And Treatment (Value)
      • 7.2.1. Global Neuropsychiatric Disorders And Treatment by: Types (Value)
        • 7.2.1.1. Degenerative Diseases
        • 7.2.1.2. Psychosis
        • 7.2.1.3. Neurotic Disorder
      • 7.2.2. Global Neuropsychiatric Disorders And Treatment by: End Users (Value)
        • 7.2.2.1. Hospitals
        • 7.2.2.2. Specialty Clinics
        • 7.2.2.3. Research & Development Centers
        • 7.2.2.4. Academic Institutions
        • 7.2.2.5. Others
      • 7.2.3. Global Neuropsychiatric Disorders And Treatment by: Route of Administration (Value)
        • 7.2.3.1. Oral
        • 7.2.3.2. Parenteral
      • 7.2.4. Global Neuropsychiatric Disorders And Treatment by: Distribution Channel (Value)
        • 7.2.4.1. Hospital Pharmacy
        • 7.2.4.2. Retail Pharmacy
        • 7.2.4.3. Online Pharmacy
        • 7.2.4.4. Others
      • 7.2.5. Global Neuropsychiatric Disorders And Treatment by: Treatments (Value)
        • 7.2.5.1. Shock Treatments
        • 7.2.5.2. Drug Treatments
        • 7.2.5.3. Others
      • 7.2.6. Global Neuropsychiatric Disorders And Treatment by: Drug Class (Value)
        • 7.2.6.1. Cholinesterase Inhibitors
        • 7.2.6.2. NMDA Receptor Antagonists
        • 7.2.6.3. Antiepileptic
        • 7.2.6.4. Antipsychotic
        • 7.2.6.5. Antidepressant
        • 7.2.6.6. Others
      • 7.2.7. Global Neuropsychiatric Disorders And Treatment Region
        • 7.2.7.1. South America
          • 7.2.7.1.1. Brazil
          • 7.2.7.1.2. Argentina
          • 7.2.7.1.3. Rest of South America
        • 7.2.7.2. Asia Pacific
          • 7.2.7.2.1. China
          • 7.2.7.2.2. Japan
          • 7.2.7.2.3. India
          • 7.2.7.2.4. South Korea
          • 7.2.7.2.5. Taiwan
          • 7.2.7.2.6. Australia
          • 7.2.7.2.7. Rest of Asia-Pacific
        • 7.2.7.3. Europe
          • 7.2.7.3.1. Germany
          • 7.2.7.3.2. France
          • 7.2.7.3.3. Italy
          • 7.2.7.3.4. United Kingdom
          • 7.2.7.3.5. Netherlands
          • 7.2.7.3.6. Rest of Europe
        • 7.2.7.4. MEA
          • 7.2.7.4.1. Middle East
          • 7.2.7.4.2. Africa
        • 7.2.7.5. North America
          • 7.2.7.5.1. United States
          • 7.2.7.5.2. Canada
          • 7.2.7.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Neuropsychiatric Disorders And Treatment: by Types(USD Million)
  • Table 2. Neuropsychiatric Disorders And Treatment Degenerative Diseases , by Region USD Million (2017-2022)
  • Table 3. Neuropsychiatric Disorders And Treatment Psychosis , by Region USD Million (2017-2022)
  • Table 4. Neuropsychiatric Disorders And Treatment Neurotic Disorder , by Region USD Million (2017-2022)
  • Table 5. Neuropsychiatric Disorders And Treatment: by End Users(USD Million)
  • Table 6. Neuropsychiatric Disorders And Treatment Hospitals , by Region USD Million (2017-2022)
  • Table 7. Neuropsychiatric Disorders And Treatment Specialty Clinics , by Region USD Million (2017-2022)
  • Table 8. Neuropsychiatric Disorders And Treatment Research & Development Centers , by Region USD Million (2017-2022)
  • Table 9. Neuropsychiatric Disorders And Treatment Academic Institutions , by Region USD Million (2017-2022)
  • Table 10. Neuropsychiatric Disorders And Treatment Others , by Region USD Million (2017-2022)
  • Table 11. Neuropsychiatric Disorders And Treatment: by Route of Administration(USD Million)
  • Table 12. Neuropsychiatric Disorders And Treatment Oral , by Region USD Million (2017-2022)
  • Table 13. Neuropsychiatric Disorders And Treatment Parenteral , by Region USD Million (2017-2022)
  • Table 14. Neuropsychiatric Disorders And Treatment: by Distribution Channel(USD Million)
  • Table 15. Neuropsychiatric Disorders And Treatment Hospital Pharmacy , by Region USD Million (2017-2022)
  • Table 16. Neuropsychiatric Disorders And Treatment Retail Pharmacy , by Region USD Million (2017-2022)
  • Table 17. Neuropsychiatric Disorders And Treatment Online Pharmacy , by Region USD Million (2017-2022)
  • Table 18. Neuropsychiatric Disorders And Treatment Others , by Region USD Million (2017-2022)
  • Table 19. Neuropsychiatric Disorders And Treatment: by Treatments(USD Million)
  • Table 20. Neuropsychiatric Disorders And Treatment Shock Treatments , by Region USD Million (2017-2022)
  • Table 21. Neuropsychiatric Disorders And Treatment Drug Treatments , by Region USD Million (2017-2022)
  • Table 22. Neuropsychiatric Disorders And Treatment Others , by Region USD Million (2017-2022)
  • Table 23. Neuropsychiatric Disorders And Treatment: by Drug Class(USD Million)
  • Table 24. Neuropsychiatric Disorders And Treatment Cholinesterase Inhibitors , by Region USD Million (2017-2022)
  • Table 25. Neuropsychiatric Disorders And Treatment NMDA Receptor Antagonists , by Region USD Million (2017-2022)
  • Table 26. Neuropsychiatric Disorders And Treatment Antiepileptic , by Region USD Million (2017-2022)
  • Table 27. Neuropsychiatric Disorders And Treatment Antipsychotic , by Region USD Million (2017-2022)
  • Table 28. Neuropsychiatric Disorders And Treatment Antidepressant , by Region USD Million (2017-2022)
  • Table 29. Neuropsychiatric Disorders And Treatment Others , by Region USD Million (2017-2022)
  • Table 30. South America Neuropsychiatric Disorders And Treatment, by Country USD Million (2017-2022)
  • Table 31. South America Neuropsychiatric Disorders And Treatment, by Types USD Million (2017-2022)
  • Table 32. South America Neuropsychiatric Disorders And Treatment, by End Users USD Million (2017-2022)
  • Table 33. South America Neuropsychiatric Disorders And Treatment, by Route of Administration USD Million (2017-2022)
  • Table 34. South America Neuropsychiatric Disorders And Treatment, by Distribution Channel USD Million (2017-2022)
  • Table 35. South America Neuropsychiatric Disorders And Treatment, by Treatments USD Million (2017-2022)
  • Table 36. South America Neuropsychiatric Disorders And Treatment, by Drug Class USD Million (2017-2022)
  • Table 37. Brazil Neuropsychiatric Disorders And Treatment, by Types USD Million (2017-2022)
  • Table 38. Brazil Neuropsychiatric Disorders And Treatment, by End Users USD Million (2017-2022)
  • Table 39. Brazil Neuropsychiatric Disorders And Treatment, by Route of Administration USD Million (2017-2022)
  • Table 40. Brazil Neuropsychiatric Disorders And Treatment, by Distribution Channel USD Million (2017-2022)
  • Table 41. Brazil Neuropsychiatric Disorders And Treatment, by Treatments USD Million (2017-2022)
  • Table 42. Brazil Neuropsychiatric Disorders And Treatment, by Drug Class USD Million (2017-2022)
  • Table 43. Argentina Neuropsychiatric Disorders And Treatment, by Types USD Million (2017-2022)
  • Table 44. Argentina Neuropsychiatric Disorders And Treatment, by End Users USD Million (2017-2022)
  • Table 45. Argentina Neuropsychiatric Disorders And Treatment, by Route of Administration USD Million (2017-2022)
  • Table 46. Argentina Neuropsychiatric Disorders And Treatment, by Distribution Channel USD Million (2017-2022)
  • Table 47. Argentina Neuropsychiatric Disorders And Treatment, by Treatments USD Million (2017-2022)
  • Table 48. Argentina Neuropsychiatric Disorders And Treatment, by Drug Class USD Million (2017-2022)
  • Table 49. Rest of South America Neuropsychiatric Disorders And Treatment, by Types USD Million (2017-2022)
  • Table 50. Rest of South America Neuropsychiatric Disorders And Treatment, by End Users USD Million (2017-2022)
  • Table 51. Rest of South America Neuropsychiatric Disorders And Treatment, by Route of Administration USD Million (2017-2022)
  • Table 52. Rest of South America Neuropsychiatric Disorders And Treatment, by Distribution Channel USD Million (2017-2022)
  • Table 53. Rest of South America Neuropsychiatric Disorders And Treatment, by Treatments USD Million (2017-2022)
  • Table 54. Rest of South America Neuropsychiatric Disorders And Treatment, by Drug Class USD Million (2017-2022)
  • Table 55. Asia Pacific Neuropsychiatric Disorders And Treatment, by Country USD Million (2017-2022)
  • Table 56. Asia Pacific Neuropsychiatric Disorders And Treatment, by Types USD Million (2017-2022)
  • Table 57. Asia Pacific Neuropsychiatric Disorders And Treatment, by End Users USD Million (2017-2022)
  • Table 58. Asia Pacific Neuropsychiatric Disorders And Treatment, by Route of Administration USD Million (2017-2022)
  • Table 59. Asia Pacific Neuropsychiatric Disorders And Treatment, by Distribution Channel USD Million (2017-2022)
  • Table 60. Asia Pacific Neuropsychiatric Disorders And Treatment, by Treatments USD Million (2017-2022)
  • Table 61. Asia Pacific Neuropsychiatric Disorders And Treatment, by Drug Class USD Million (2017-2022)
  • Table 62. China Neuropsychiatric Disorders And Treatment, by Types USD Million (2017-2022)
  • Table 63. China Neuropsychiatric Disorders And Treatment, by End Users USD Million (2017-2022)
  • Table 64. China Neuropsychiatric Disorders And Treatment, by Route of Administration USD Million (2017-2022)
  • Table 65. China Neuropsychiatric Disorders And Treatment, by Distribution Channel USD Million (2017-2022)
  • Table 66. China Neuropsychiatric Disorders And Treatment, by Treatments USD Million (2017-2022)
  • Table 67. China Neuropsychiatric Disorders And Treatment, by Drug Class USD Million (2017-2022)
  • Table 68. Japan Neuropsychiatric Disorders And Treatment, by Types USD Million (2017-2022)
  • Table 69. Japan Neuropsychiatric Disorders And Treatment, by End Users USD Million (2017-2022)
  • Table 70. Japan Neuropsychiatric Disorders And Treatment, by Route of Administration USD Million (2017-2022)
  • Table 71. Japan Neuropsychiatric Disorders And Treatment, by Distribution Channel USD Million (2017-2022)
  • Table 72. Japan Neuropsychiatric Disorders And Treatment, by Treatments USD Million (2017-2022)
  • Table 73. Japan Neuropsychiatric Disorders And Treatment, by Drug Class USD Million (2017-2022)
  • Table 74. India Neuropsychiatric Disorders And Treatment, by Types USD Million (2017-2022)
  • Table 75. India Neuropsychiatric Disorders And Treatment, by End Users USD Million (2017-2022)
  • Table 76. India Neuropsychiatric Disorders And Treatment, by Route of Administration USD Million (2017-2022)
  • Table 77. India Neuropsychiatric Disorders And Treatment, by Distribution Channel USD Million (2017-2022)
  • Table 78. India Neuropsychiatric Disorders And Treatment, by Treatments USD Million (2017-2022)
  • Table 79. India Neuropsychiatric Disorders And Treatment, by Drug Class USD Million (2017-2022)
  • Table 80. South Korea Neuropsychiatric Disorders And Treatment, by Types USD Million (2017-2022)
  • Table 81. South Korea Neuropsychiatric Disorders And Treatment, by End Users USD Million (2017-2022)
  • Table 82. South Korea Neuropsychiatric Disorders And Treatment, by Route of Administration USD Million (2017-2022)
  • Table 83. South Korea Neuropsychiatric Disorders And Treatment, by Distribution Channel USD Million (2017-2022)
  • Table 84. South Korea Neuropsychiatric Disorders And Treatment, by Treatments USD Million (2017-2022)
  • Table 85. South Korea Neuropsychiatric Disorders And Treatment, by Drug Class USD Million (2017-2022)
  • Table 86. Taiwan Neuropsychiatric Disorders And Treatment, by Types USD Million (2017-2022)
  • Table 87. Taiwan Neuropsychiatric Disorders And Treatment, by End Users USD Million (2017-2022)
  • Table 88. Taiwan Neuropsychiatric Disorders And Treatment, by Route of Administration USD Million (2017-2022)
  • Table 89. Taiwan Neuropsychiatric Disorders And Treatment, by Distribution Channel USD Million (2017-2022)
  • Table 90. Taiwan Neuropsychiatric Disorders And Treatment, by Treatments USD Million (2017-2022)
  • Table 91. Taiwan Neuropsychiatric Disorders And Treatment, by Drug Class USD Million (2017-2022)
  • Table 92. Australia Neuropsychiatric Disorders And Treatment, by Types USD Million (2017-2022)
  • Table 93. Australia Neuropsychiatric Disorders And Treatment, by End Users USD Million (2017-2022)
  • Table 94. Australia Neuropsychiatric Disorders And Treatment, by Route of Administration USD Million (2017-2022)
  • Table 95. Australia Neuropsychiatric Disorders And Treatment, by Distribution Channel USD Million (2017-2022)
  • Table 96. Australia Neuropsychiatric Disorders And Treatment, by Treatments USD Million (2017-2022)
  • Table 97. Australia Neuropsychiatric Disorders And Treatment, by Drug Class USD Million (2017-2022)
  • Table 98. Rest of Asia-Pacific Neuropsychiatric Disorders And Treatment, by Types USD Million (2017-2022)
  • Table 99. Rest of Asia-Pacific Neuropsychiatric Disorders And Treatment, by End Users USD Million (2017-2022)
  • Table 100. Rest of Asia-Pacific Neuropsychiatric Disorders And Treatment, by Route of Administration USD Million (2017-2022)
  • Table 101. Rest of Asia-Pacific Neuropsychiatric Disorders And Treatment, by Distribution Channel USD Million (2017-2022)
  • Table 102. Rest of Asia-Pacific Neuropsychiatric Disorders And Treatment, by Treatments USD Million (2017-2022)
  • Table 103. Rest of Asia-Pacific Neuropsychiatric Disorders And Treatment, by Drug Class USD Million (2017-2022)
  • Table 104. Europe Neuropsychiatric Disorders And Treatment, by Country USD Million (2017-2022)
  • Table 105. Europe Neuropsychiatric Disorders And Treatment, by Types USD Million (2017-2022)
  • Table 106. Europe Neuropsychiatric Disorders And Treatment, by End Users USD Million (2017-2022)
  • Table 107. Europe Neuropsychiatric Disorders And Treatment, by Route of Administration USD Million (2017-2022)
  • Table 108. Europe Neuropsychiatric Disorders And Treatment, by Distribution Channel USD Million (2017-2022)
  • Table 109. Europe Neuropsychiatric Disorders And Treatment, by Treatments USD Million (2017-2022)
  • Table 110. Europe Neuropsychiatric Disorders And Treatment, by Drug Class USD Million (2017-2022)
  • Table 111. Germany Neuropsychiatric Disorders And Treatment, by Types USD Million (2017-2022)
  • Table 112. Germany Neuropsychiatric Disorders And Treatment, by End Users USD Million (2017-2022)
  • Table 113. Germany Neuropsychiatric Disorders And Treatment, by Route of Administration USD Million (2017-2022)
  • Table 114. Germany Neuropsychiatric Disorders And Treatment, by Distribution Channel USD Million (2017-2022)
  • Table 115. Germany Neuropsychiatric Disorders And Treatment, by Treatments USD Million (2017-2022)
  • Table 116. Germany Neuropsychiatric Disorders And Treatment, by Drug Class USD Million (2017-2022)
  • Table 117. France Neuropsychiatric Disorders And Treatment, by Types USD Million (2017-2022)
  • Table 118. France Neuropsychiatric Disorders And Treatment, by End Users USD Million (2017-2022)
  • Table 119. France Neuropsychiatric Disorders And Treatment, by Route of Administration USD Million (2017-2022)
  • Table 120. France Neuropsychiatric Disorders And Treatment, by Distribution Channel USD Million (2017-2022)
  • Table 121. France Neuropsychiatric Disorders And Treatment, by Treatments USD Million (2017-2022)
  • Table 122. France Neuropsychiatric Disorders And Treatment, by Drug Class USD Million (2017-2022)
  • Table 123. Italy Neuropsychiatric Disorders And Treatment, by Types USD Million (2017-2022)
  • Table 124. Italy Neuropsychiatric Disorders And Treatment, by End Users USD Million (2017-2022)
  • Table 125. Italy Neuropsychiatric Disorders And Treatment, by Route of Administration USD Million (2017-2022)
  • Table 126. Italy Neuropsychiatric Disorders And Treatment, by Distribution Channel USD Million (2017-2022)
  • Table 127. Italy Neuropsychiatric Disorders And Treatment, by Treatments USD Million (2017-2022)
  • Table 128. Italy Neuropsychiatric Disorders And Treatment, by Drug Class USD Million (2017-2022)
  • Table 129. United Kingdom Neuropsychiatric Disorders And Treatment, by Types USD Million (2017-2022)
  • Table 130. United Kingdom Neuropsychiatric Disorders And Treatment, by End Users USD Million (2017-2022)
  • Table 131. United Kingdom Neuropsychiatric Disorders And Treatment, by Route of Administration USD Million (2017-2022)
  • Table 132. United Kingdom Neuropsychiatric Disorders And Treatment, by Distribution Channel USD Million (2017-2022)
  • Table 133. United Kingdom Neuropsychiatric Disorders And Treatment, by Treatments USD Million (2017-2022)
  • Table 134. United Kingdom Neuropsychiatric Disorders And Treatment, by Drug Class USD Million (2017-2022)
  • Table 135. Netherlands Neuropsychiatric Disorders And Treatment, by Types USD Million (2017-2022)
  • Table 136. Netherlands Neuropsychiatric Disorders And Treatment, by End Users USD Million (2017-2022)
  • Table 137. Netherlands Neuropsychiatric Disorders And Treatment, by Route of Administration USD Million (2017-2022)
  • Table 138. Netherlands Neuropsychiatric Disorders And Treatment, by Distribution Channel USD Million (2017-2022)
  • Table 139. Netherlands Neuropsychiatric Disorders And Treatment, by Treatments USD Million (2017-2022)
  • Table 140. Netherlands Neuropsychiatric Disorders And Treatment, by Drug Class USD Million (2017-2022)
  • Table 141. Rest of Europe Neuropsychiatric Disorders And Treatment, by Types USD Million (2017-2022)
  • Table 142. Rest of Europe Neuropsychiatric Disorders And Treatment, by End Users USD Million (2017-2022)
  • Table 143. Rest of Europe Neuropsychiatric Disorders And Treatment, by Route of Administration USD Million (2017-2022)
  • Table 144. Rest of Europe Neuropsychiatric Disorders And Treatment, by Distribution Channel USD Million (2017-2022)
  • Table 145. Rest of Europe Neuropsychiatric Disorders And Treatment, by Treatments USD Million (2017-2022)
  • Table 146. Rest of Europe Neuropsychiatric Disorders And Treatment, by Drug Class USD Million (2017-2022)
  • Table 147. MEA Neuropsychiatric Disorders And Treatment, by Country USD Million (2017-2022)
  • Table 148. MEA Neuropsychiatric Disorders And Treatment, by Types USD Million (2017-2022)
  • Table 149. MEA Neuropsychiatric Disorders And Treatment, by End Users USD Million (2017-2022)
  • Table 150. MEA Neuropsychiatric Disorders And Treatment, by Route of Administration USD Million (2017-2022)
  • Table 151. MEA Neuropsychiatric Disorders And Treatment, by Distribution Channel USD Million (2017-2022)
  • Table 152. MEA Neuropsychiatric Disorders And Treatment, by Treatments USD Million (2017-2022)
  • Table 153. MEA Neuropsychiatric Disorders And Treatment, by Drug Class USD Million (2017-2022)
  • Table 154. Middle East Neuropsychiatric Disorders And Treatment, by Types USD Million (2017-2022)
  • Table 155. Middle East Neuropsychiatric Disorders And Treatment, by End Users USD Million (2017-2022)
  • Table 156. Middle East Neuropsychiatric Disorders And Treatment, by Route of Administration USD Million (2017-2022)
  • Table 157. Middle East Neuropsychiatric Disorders And Treatment, by Distribution Channel USD Million (2017-2022)
  • Table 158. Middle East Neuropsychiatric Disorders And Treatment, by Treatments USD Million (2017-2022)
  • Table 159. Middle East Neuropsychiatric Disorders And Treatment, by Drug Class USD Million (2017-2022)
  • Table 160. Africa Neuropsychiatric Disorders And Treatment, by Types USD Million (2017-2022)
  • Table 161. Africa Neuropsychiatric Disorders And Treatment, by End Users USD Million (2017-2022)
  • Table 162. Africa Neuropsychiatric Disorders And Treatment, by Route of Administration USD Million (2017-2022)
  • Table 163. Africa Neuropsychiatric Disorders And Treatment, by Distribution Channel USD Million (2017-2022)
  • Table 164. Africa Neuropsychiatric Disorders And Treatment, by Treatments USD Million (2017-2022)
  • Table 165. Africa Neuropsychiatric Disorders And Treatment, by Drug Class USD Million (2017-2022)
  • Table 166. North America Neuropsychiatric Disorders And Treatment, by Country USD Million (2017-2022)
  • Table 167. North America Neuropsychiatric Disorders And Treatment, by Types USD Million (2017-2022)
  • Table 168. North America Neuropsychiatric Disorders And Treatment, by End Users USD Million (2017-2022)
  • Table 169. North America Neuropsychiatric Disorders And Treatment, by Route of Administration USD Million (2017-2022)
  • Table 170. North America Neuropsychiatric Disorders And Treatment, by Distribution Channel USD Million (2017-2022)
  • Table 171. North America Neuropsychiatric Disorders And Treatment, by Treatments USD Million (2017-2022)
  • Table 172. North America Neuropsychiatric Disorders And Treatment, by Drug Class USD Million (2017-2022)
  • Table 173. United States Neuropsychiatric Disorders And Treatment, by Types USD Million (2017-2022)
  • Table 174. United States Neuropsychiatric Disorders And Treatment, by End Users USD Million (2017-2022)
  • Table 175. United States Neuropsychiatric Disorders And Treatment, by Route of Administration USD Million (2017-2022)
  • Table 176. United States Neuropsychiatric Disorders And Treatment, by Distribution Channel USD Million (2017-2022)
  • Table 177. United States Neuropsychiatric Disorders And Treatment, by Treatments USD Million (2017-2022)
  • Table 178. United States Neuropsychiatric Disorders And Treatment, by Drug Class USD Million (2017-2022)
  • Table 179. Canada Neuropsychiatric Disorders And Treatment, by Types USD Million (2017-2022)
  • Table 180. Canada Neuropsychiatric Disorders And Treatment, by End Users USD Million (2017-2022)
  • Table 181. Canada Neuropsychiatric Disorders And Treatment, by Route of Administration USD Million (2017-2022)
  • Table 182. Canada Neuropsychiatric Disorders And Treatment, by Distribution Channel USD Million (2017-2022)
  • Table 183. Canada Neuropsychiatric Disorders And Treatment, by Treatments USD Million (2017-2022)
  • Table 184. Canada Neuropsychiatric Disorders And Treatment, by Drug Class USD Million (2017-2022)
  • Table 185. Mexico Neuropsychiatric Disorders And Treatment, by Types USD Million (2017-2022)
  • Table 186. Mexico Neuropsychiatric Disorders And Treatment, by End Users USD Million (2017-2022)
  • Table 187. Mexico Neuropsychiatric Disorders And Treatment, by Route of Administration USD Million (2017-2022)
  • Table 188. Mexico Neuropsychiatric Disorders And Treatment, by Distribution Channel USD Million (2017-2022)
  • Table 189. Mexico Neuropsychiatric Disorders And Treatment, by Treatments USD Million (2017-2022)
  • Table 190. Mexico Neuropsychiatric Disorders And Treatment, by Drug Class USD Million (2017-2022)
  • Table 191. Company Basic Information, Sales Area and Its Competitors
  • Table 192. Company Basic Information, Sales Area and Its Competitors
  • Table 193. Company Basic Information, Sales Area and Its Competitors
  • Table 194. Company Basic Information, Sales Area and Its Competitors
  • Table 195. Company Basic Information, Sales Area and Its Competitors
  • Table 196. Company Basic Information, Sales Area and Its Competitors
  • Table 197. Company Basic Information, Sales Area and Its Competitors
  • Table 198. Company Basic Information, Sales Area and Its Competitors
  • Table 199. Company Basic Information, Sales Area and Its Competitors
  • Table 200. Neuropsychiatric Disorders And Treatment: by Types(USD Million)
  • Table 201. Neuropsychiatric Disorders And Treatment Degenerative Diseases , by Region USD Million (2023-2028)
  • Table 202. Neuropsychiatric Disorders And Treatment Psychosis , by Region USD Million (2023-2028)
  • Table 203. Neuropsychiatric Disorders And Treatment Neurotic Disorder , by Region USD Million (2023-2028)
  • Table 204. Neuropsychiatric Disorders And Treatment: by End Users(USD Million)
  • Table 205. Neuropsychiatric Disorders And Treatment Hospitals , by Region USD Million (2023-2028)
  • Table 206. Neuropsychiatric Disorders And Treatment Specialty Clinics , by Region USD Million (2023-2028)
  • Table 207. Neuropsychiatric Disorders And Treatment Research & Development Centers , by Region USD Million (2023-2028)
  • Table 208. Neuropsychiatric Disorders And Treatment Academic Institutions , by Region USD Million (2023-2028)
  • Table 209. Neuropsychiatric Disorders And Treatment Others , by Region USD Million (2023-2028)
  • Table 210. Neuropsychiatric Disorders And Treatment: by Route of Administration(USD Million)
  • Table 211. Neuropsychiatric Disorders And Treatment Oral , by Region USD Million (2023-2028)
  • Table 212. Neuropsychiatric Disorders And Treatment Parenteral , by Region USD Million (2023-2028)
  • Table 213. Neuropsychiatric Disorders And Treatment: by Distribution Channel(USD Million)
  • Table 214. Neuropsychiatric Disorders And Treatment Hospital Pharmacy , by Region USD Million (2023-2028)
  • Table 215. Neuropsychiatric Disorders And Treatment Retail Pharmacy , by Region USD Million (2023-2028)
  • Table 216. Neuropsychiatric Disorders And Treatment Online Pharmacy , by Region USD Million (2023-2028)
  • Table 217. Neuropsychiatric Disorders And Treatment Others , by Region USD Million (2023-2028)
  • Table 218. Neuropsychiatric Disorders And Treatment: by Treatments(USD Million)
  • Table 219. Neuropsychiatric Disorders And Treatment Shock Treatments , by Region USD Million (2023-2028)
  • Table 220. Neuropsychiatric Disorders And Treatment Drug Treatments , by Region USD Million (2023-2028)
  • Table 221. Neuropsychiatric Disorders And Treatment Others , by Region USD Million (2023-2028)
  • Table 222. Neuropsychiatric Disorders And Treatment: by Drug Class(USD Million)
  • Table 223. Neuropsychiatric Disorders And Treatment Cholinesterase Inhibitors , by Region USD Million (2023-2028)
  • Table 224. Neuropsychiatric Disorders And Treatment NMDA Receptor Antagonists , by Region USD Million (2023-2028)
  • Table 225. Neuropsychiatric Disorders And Treatment Antiepileptic , by Region USD Million (2023-2028)
  • Table 226. Neuropsychiatric Disorders And Treatment Antipsychotic , by Region USD Million (2023-2028)
  • Table 227. Neuropsychiatric Disorders And Treatment Antidepressant , by Region USD Million (2023-2028)
  • Table 228. Neuropsychiatric Disorders And Treatment Others , by Region USD Million (2023-2028)
  • Table 229. South America Neuropsychiatric Disorders And Treatment, by Country USD Million (2023-2028)
  • Table 230. South America Neuropsychiatric Disorders And Treatment, by Types USD Million (2023-2028)
  • Table 231. South America Neuropsychiatric Disorders And Treatment, by End Users USD Million (2023-2028)
  • Table 232. South America Neuropsychiatric Disorders And Treatment, by Route of Administration USD Million (2023-2028)
  • Table 233. South America Neuropsychiatric Disorders And Treatment, by Distribution Channel USD Million (2023-2028)
  • Table 234. South America Neuropsychiatric Disorders And Treatment, by Treatments USD Million (2023-2028)
  • Table 235. South America Neuropsychiatric Disorders And Treatment, by Drug Class USD Million (2023-2028)
  • Table 236. Brazil Neuropsychiatric Disorders And Treatment, by Types USD Million (2023-2028)
  • Table 237. Brazil Neuropsychiatric Disorders And Treatment, by End Users USD Million (2023-2028)
  • Table 238. Brazil Neuropsychiatric Disorders And Treatment, by Route of Administration USD Million (2023-2028)
  • Table 239. Brazil Neuropsychiatric Disorders And Treatment, by Distribution Channel USD Million (2023-2028)
  • Table 240. Brazil Neuropsychiatric Disorders And Treatment, by Treatments USD Million (2023-2028)
  • Table 241. Brazil Neuropsychiatric Disorders And Treatment, by Drug Class USD Million (2023-2028)
  • Table 242. Argentina Neuropsychiatric Disorders And Treatment, by Types USD Million (2023-2028)
  • Table 243. Argentina Neuropsychiatric Disorders And Treatment, by End Users USD Million (2023-2028)
  • Table 244. Argentina Neuropsychiatric Disorders And Treatment, by Route of Administration USD Million (2023-2028)
  • Table 245. Argentina Neuropsychiatric Disorders And Treatment, by Distribution Channel USD Million (2023-2028)
  • Table 246. Argentina Neuropsychiatric Disorders And Treatment, by Treatments USD Million (2023-2028)
  • Table 247. Argentina Neuropsychiatric Disorders And Treatment, by Drug Class USD Million (2023-2028)
  • Table 248. Rest of South America Neuropsychiatric Disorders And Treatment, by Types USD Million (2023-2028)
  • Table 249. Rest of South America Neuropsychiatric Disorders And Treatment, by End Users USD Million (2023-2028)
  • Table 250. Rest of South America Neuropsychiatric Disorders And Treatment, by Route of Administration USD Million (2023-2028)
  • Table 251. Rest of South America Neuropsychiatric Disorders And Treatment, by Distribution Channel USD Million (2023-2028)
  • Table 252. Rest of South America Neuropsychiatric Disorders And Treatment, by Treatments USD Million (2023-2028)
  • Table 253. Rest of South America Neuropsychiatric Disorders And Treatment, by Drug Class USD Million (2023-2028)
  • Table 254. Asia Pacific Neuropsychiatric Disorders And Treatment, by Country USD Million (2023-2028)
  • Table 255. Asia Pacific Neuropsychiatric Disorders And Treatment, by Types USD Million (2023-2028)
  • Table 256. Asia Pacific Neuropsychiatric Disorders And Treatment, by End Users USD Million (2023-2028)
  • Table 257. Asia Pacific Neuropsychiatric Disorders And Treatment, by Route of Administration USD Million (2023-2028)
  • Table 258. Asia Pacific Neuropsychiatric Disorders And Treatment, by Distribution Channel USD Million (2023-2028)
  • Table 259. Asia Pacific Neuropsychiatric Disorders And Treatment, by Treatments USD Million (2023-2028)
  • Table 260. Asia Pacific Neuropsychiatric Disorders And Treatment, by Drug Class USD Million (2023-2028)
  • Table 261. China Neuropsychiatric Disorders And Treatment, by Types USD Million (2023-2028)
  • Table 262. China Neuropsychiatric Disorders And Treatment, by End Users USD Million (2023-2028)
  • Table 263. China Neuropsychiatric Disorders And Treatment, by Route of Administration USD Million (2023-2028)
  • Table 264. China Neuropsychiatric Disorders And Treatment, by Distribution Channel USD Million (2023-2028)
  • Table 265. China Neuropsychiatric Disorders And Treatment, by Treatments USD Million (2023-2028)
  • Table 266. China Neuropsychiatric Disorders And Treatment, by Drug Class USD Million (2023-2028)
  • Table 267. Japan Neuropsychiatric Disorders And Treatment, by Types USD Million (2023-2028)
  • Table 268. Japan Neuropsychiatric Disorders And Treatment, by End Users USD Million (2023-2028)
  • Table 269. Japan Neuropsychiatric Disorders And Treatment, by Route of Administration USD Million (2023-2028)
  • Table 270. Japan Neuropsychiatric Disorders And Treatment, by Distribution Channel USD Million (2023-2028)
  • Table 271. Japan Neuropsychiatric Disorders And Treatment, by Treatments USD Million (2023-2028)
  • Table 272. Japan Neuropsychiatric Disorders And Treatment, by Drug Class USD Million (2023-2028)
  • Table 273. India Neuropsychiatric Disorders And Treatment, by Types USD Million (2023-2028)
  • Table 274. India Neuropsychiatric Disorders And Treatment, by End Users USD Million (2023-2028)
  • Table 275. India Neuropsychiatric Disorders And Treatment, by Route of Administration USD Million (2023-2028)
  • Table 276. India Neuropsychiatric Disorders And Treatment, by Distribution Channel USD Million (2023-2028)
  • Table 277. India Neuropsychiatric Disorders And Treatment, by Treatments USD Million (2023-2028)
  • Table 278. India Neuropsychiatric Disorders And Treatment, by Drug Class USD Million (2023-2028)
  • Table 279. South Korea Neuropsychiatric Disorders And Treatment, by Types USD Million (2023-2028)
  • Table 280. South Korea Neuropsychiatric Disorders And Treatment, by End Users USD Million (2023-2028)
  • Table 281. South Korea Neuropsychiatric Disorders And Treatment, by Route of Administration USD Million (2023-2028)
  • Table 282. South Korea Neuropsychiatric Disorders And Treatment, by Distribution Channel USD Million (2023-2028)
  • Table 283. South Korea Neuropsychiatric Disorders And Treatment, by Treatments USD Million (2023-2028)
  • Table 284. South Korea Neuropsychiatric Disorders And Treatment, by Drug Class USD Million (2023-2028)
  • Table 285. Taiwan Neuropsychiatric Disorders And Treatment, by Types USD Million (2023-2028)
  • Table 286. Taiwan Neuropsychiatric Disorders And Treatment, by End Users USD Million (2023-2028)
  • Table 287. Taiwan Neuropsychiatric Disorders And Treatment, by Route of Administration USD Million (2023-2028)
  • Table 288. Taiwan Neuropsychiatric Disorders And Treatment, by Distribution Channel USD Million (2023-2028)
  • Table 289. Taiwan Neuropsychiatric Disorders And Treatment, by Treatments USD Million (2023-2028)
  • Table 290. Taiwan Neuropsychiatric Disorders And Treatment, by Drug Class USD Million (2023-2028)
  • Table 291. Australia Neuropsychiatric Disorders And Treatment, by Types USD Million (2023-2028)
  • Table 292. Australia Neuropsychiatric Disorders And Treatment, by End Users USD Million (2023-2028)
  • Table 293. Australia Neuropsychiatric Disorders And Treatment, by Route of Administration USD Million (2023-2028)
  • Table 294. Australia Neuropsychiatric Disorders And Treatment, by Distribution Channel USD Million (2023-2028)
  • Table 295. Australia Neuropsychiatric Disorders And Treatment, by Treatments USD Million (2023-2028)
  • Table 296. Australia Neuropsychiatric Disorders And Treatment, by Drug Class USD Million (2023-2028)
  • Table 297. Rest of Asia-Pacific Neuropsychiatric Disorders And Treatment, by Types USD Million (2023-2028)
  • Table 298. Rest of Asia-Pacific Neuropsychiatric Disorders And Treatment, by End Users USD Million (2023-2028)
  • Table 299. Rest of Asia-Pacific Neuropsychiatric Disorders And Treatment, by Route of Administration USD Million (2023-2028)
  • Table 300. Rest of Asia-Pacific Neuropsychiatric Disorders And Treatment, by Distribution Channel USD Million (2023-2028)
  • Table 301. Rest of Asia-Pacific Neuropsychiatric Disorders And Treatment, by Treatments USD Million (2023-2028)
  • Table 302. Rest of Asia-Pacific Neuropsychiatric Disorders And Treatment, by Drug Class USD Million (2023-2028)
  • Table 303. Europe Neuropsychiatric Disorders And Treatment, by Country USD Million (2023-2028)
  • Table 304. Europe Neuropsychiatric Disorders And Treatment, by Types USD Million (2023-2028)
  • Table 305. Europe Neuropsychiatric Disorders And Treatment, by End Users USD Million (2023-2028)
  • Table 306. Europe Neuropsychiatric Disorders And Treatment, by Route of Administration USD Million (2023-2028)
  • Table 307. Europe Neuropsychiatric Disorders And Treatment, by Distribution Channel USD Million (2023-2028)
  • Table 308. Europe Neuropsychiatric Disorders And Treatment, by Treatments USD Million (2023-2028)
  • Table 309. Europe Neuropsychiatric Disorders And Treatment, by Drug Class USD Million (2023-2028)
  • Table 310. Germany Neuropsychiatric Disorders And Treatment, by Types USD Million (2023-2028)
  • Table 311. Germany Neuropsychiatric Disorders And Treatment, by End Users USD Million (2023-2028)
  • Table 312. Germany Neuropsychiatric Disorders And Treatment, by Route of Administration USD Million (2023-2028)
  • Table 313. Germany Neuropsychiatric Disorders And Treatment, by Distribution Channel USD Million (2023-2028)
  • Table 314. Germany Neuropsychiatric Disorders And Treatment, by Treatments USD Million (2023-2028)
  • Table 315. Germany Neuropsychiatric Disorders And Treatment, by Drug Class USD Million (2023-2028)
  • Table 316. France Neuropsychiatric Disorders And Treatment, by Types USD Million (2023-2028)
  • Table 317. France Neuropsychiatric Disorders And Treatment, by End Users USD Million (2023-2028)
  • Table 318. France Neuropsychiatric Disorders And Treatment, by Route of Administration USD Million (2023-2028)
  • Table 319. France Neuropsychiatric Disorders And Treatment, by Distribution Channel USD Million (2023-2028)
  • Table 320. France Neuropsychiatric Disorders And Treatment, by Treatments USD Million (2023-2028)
  • Table 321. France Neuropsychiatric Disorders And Treatment, by Drug Class USD Million (2023-2028)
  • Table 322. Italy Neuropsychiatric Disorders And Treatment, by Types USD Million (2023-2028)
  • Table 323. Italy Neuropsychiatric Disorders And Treatment, by End Users USD Million (2023-2028)
  • Table 324. Italy Neuropsychiatric Disorders And Treatment, by Route of Administration USD Million (2023-2028)
  • Table 325. Italy Neuropsychiatric Disorders And Treatment, by Distribution Channel USD Million (2023-2028)
  • Table 326. Italy Neuropsychiatric Disorders And Treatment, by Treatments USD Million (2023-2028)
  • Table 327. Italy Neuropsychiatric Disorders And Treatment, by Drug Class USD Million (2023-2028)
  • Table 328. United Kingdom Neuropsychiatric Disorders And Treatment, by Types USD Million (2023-2028)
  • Table 329. United Kingdom Neuropsychiatric Disorders And Treatment, by End Users USD Million (2023-2028)
  • Table 330. United Kingdom Neuropsychiatric Disorders And Treatment, by Route of Administration USD Million (2023-2028)
  • Table 331. United Kingdom Neuropsychiatric Disorders And Treatment, by Distribution Channel USD Million (2023-2028)
  • Table 332. United Kingdom Neuropsychiatric Disorders And Treatment, by Treatments USD Million (2023-2028)
  • Table 333. United Kingdom Neuropsychiatric Disorders And Treatment, by Drug Class USD Million (2023-2028)
  • Table 334. Netherlands Neuropsychiatric Disorders And Treatment, by Types USD Million (2023-2028)
  • Table 335. Netherlands Neuropsychiatric Disorders And Treatment, by End Users USD Million (2023-2028)
  • Table 336. Netherlands Neuropsychiatric Disorders And Treatment, by Route of Administration USD Million (2023-2028)
  • Table 337. Netherlands Neuropsychiatric Disorders And Treatment, by Distribution Channel USD Million (2023-2028)
  • Table 338. Netherlands Neuropsychiatric Disorders And Treatment, by Treatments USD Million (2023-2028)
  • Table 339. Netherlands Neuropsychiatric Disorders And Treatment, by Drug Class USD Million (2023-2028)
  • Table 340. Rest of Europe Neuropsychiatric Disorders And Treatment, by Types USD Million (2023-2028)
  • Table 341. Rest of Europe Neuropsychiatric Disorders And Treatment, by End Users USD Million (2023-2028)
  • Table 342. Rest of Europe Neuropsychiatric Disorders And Treatment, by Route of Administration USD Million (2023-2028)
  • Table 343. Rest of Europe Neuropsychiatric Disorders And Treatment, by Distribution Channel USD Million (2023-2028)
  • Table 344. Rest of Europe Neuropsychiatric Disorders And Treatment, by Treatments USD Million (2023-2028)
  • Table 345. Rest of Europe Neuropsychiatric Disorders And Treatment, by Drug Class USD Million (2023-2028)
  • Table 346. MEA Neuropsychiatric Disorders And Treatment, by Country USD Million (2023-2028)
  • Table 347. MEA Neuropsychiatric Disorders And Treatment, by Types USD Million (2023-2028)
  • Table 348. MEA Neuropsychiatric Disorders And Treatment, by End Users USD Million (2023-2028)
  • Table 349. MEA Neuropsychiatric Disorders And Treatment, by Route of Administration USD Million (2023-2028)
  • Table 350. MEA Neuropsychiatric Disorders And Treatment, by Distribution Channel USD Million (2023-2028)
  • Table 351. MEA Neuropsychiatric Disorders And Treatment, by Treatments USD Million (2023-2028)
  • Table 352. MEA Neuropsychiatric Disorders And Treatment, by Drug Class USD Million (2023-2028)
  • Table 353. Middle East Neuropsychiatric Disorders And Treatment, by Types USD Million (2023-2028)
  • Table 354. Middle East Neuropsychiatric Disorders And Treatment, by End Users USD Million (2023-2028)
  • Table 355. Middle East Neuropsychiatric Disorders And Treatment, by Route of Administration USD Million (2023-2028)
  • Table 356. Middle East Neuropsychiatric Disorders And Treatment, by Distribution Channel USD Million (2023-2028)
  • Table 357. Middle East Neuropsychiatric Disorders And Treatment, by Treatments USD Million (2023-2028)
  • Table 358. Middle East Neuropsychiatric Disorders And Treatment, by Drug Class USD Million (2023-2028)
  • Table 359. Africa Neuropsychiatric Disorders And Treatment, by Types USD Million (2023-2028)
  • Table 360. Africa Neuropsychiatric Disorders And Treatment, by End Users USD Million (2023-2028)
  • Table 361. Africa Neuropsychiatric Disorders And Treatment, by Route of Administration USD Million (2023-2028)
  • Table 362. Africa Neuropsychiatric Disorders And Treatment, by Distribution Channel USD Million (2023-2028)
  • Table 363. Africa Neuropsychiatric Disorders And Treatment, by Treatments USD Million (2023-2028)
  • Table 364. Africa Neuropsychiatric Disorders And Treatment, by Drug Class USD Million (2023-2028)
  • Table 365. North America Neuropsychiatric Disorders And Treatment, by Country USD Million (2023-2028)
  • Table 366. North America Neuropsychiatric Disorders And Treatment, by Types USD Million (2023-2028)
  • Table 367. North America Neuropsychiatric Disorders And Treatment, by End Users USD Million (2023-2028)
  • Table 368. North America Neuropsychiatric Disorders And Treatment, by Route of Administration USD Million (2023-2028)
  • Table 369. North America Neuropsychiatric Disorders And Treatment, by Distribution Channel USD Million (2023-2028)
  • Table 370. North America Neuropsychiatric Disorders And Treatment, by Treatments USD Million (2023-2028)
  • Table 371. North America Neuropsychiatric Disorders And Treatment, by Drug Class USD Million (2023-2028)
  • Table 372. United States Neuropsychiatric Disorders And Treatment, by Types USD Million (2023-2028)
  • Table 373. United States Neuropsychiatric Disorders And Treatment, by End Users USD Million (2023-2028)
  • Table 374. United States Neuropsychiatric Disorders And Treatment, by Route of Administration USD Million (2023-2028)
  • Table 375. United States Neuropsychiatric Disorders And Treatment, by Distribution Channel USD Million (2023-2028)
  • Table 376. United States Neuropsychiatric Disorders And Treatment, by Treatments USD Million (2023-2028)
  • Table 377. United States Neuropsychiatric Disorders And Treatment, by Drug Class USD Million (2023-2028)
  • Table 378. Canada Neuropsychiatric Disorders And Treatment, by Types USD Million (2023-2028)
  • Table 379. Canada Neuropsychiatric Disorders And Treatment, by End Users USD Million (2023-2028)
  • Table 380. Canada Neuropsychiatric Disorders And Treatment, by Route of Administration USD Million (2023-2028)
  • Table 381. Canada Neuropsychiatric Disorders And Treatment, by Distribution Channel USD Million (2023-2028)
  • Table 382. Canada Neuropsychiatric Disorders And Treatment, by Treatments USD Million (2023-2028)
  • Table 383. Canada Neuropsychiatric Disorders And Treatment, by Drug Class USD Million (2023-2028)
  • Table 384. Mexico Neuropsychiatric Disorders And Treatment, by Types USD Million (2023-2028)
  • Table 385. Mexico Neuropsychiatric Disorders And Treatment, by End Users USD Million (2023-2028)
  • Table 386. Mexico Neuropsychiatric Disorders And Treatment, by Route of Administration USD Million (2023-2028)
  • Table 387. Mexico Neuropsychiatric Disorders And Treatment, by Distribution Channel USD Million (2023-2028)
  • Table 388. Mexico Neuropsychiatric Disorders And Treatment, by Treatments USD Million (2023-2028)
  • Table 389. Mexico Neuropsychiatric Disorders And Treatment, by Drug Class USD Million (2023-2028)
  • Table 390. Research Programs/Design for This Report
  • Table 391. Key Data Information from Secondary Sources
  • Table 392. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Neuropsychiatric Disorders And Treatment: by Types USD Million (2017-2022)
  • Figure 5. Global Neuropsychiatric Disorders And Treatment: by End Users USD Million (2017-2022)
  • Figure 6. Global Neuropsychiatric Disorders And Treatment: by Route of Administration USD Million (2017-2022)
  • Figure 7. Global Neuropsychiatric Disorders And Treatment: by Distribution Channel USD Million (2017-2022)
  • Figure 8. Global Neuropsychiatric Disorders And Treatment: by Treatments USD Million (2017-2022)
  • Figure 9. Global Neuropsychiatric Disorders And Treatment: by Drug Class USD Million (2017-2022)
  • Figure 10. South America Neuropsychiatric Disorders And Treatment Share (%), by Country
  • Figure 11. Asia Pacific Neuropsychiatric Disorders And Treatment Share (%), by Country
  • Figure 12. Europe Neuropsychiatric Disorders And Treatment Share (%), by Country
  • Figure 13. MEA Neuropsychiatric Disorders And Treatment Share (%), by Country
  • Figure 14. North America Neuropsychiatric Disorders And Treatment Share (%), by Country
  • Figure 15. Global Neuropsychiatric Disorders And Treatment share by Players 2022 (%)
  • Figure 16. Global Neuropsychiatric Disorders And Treatment share by Players (Top 3) 2022(%)
  • Figure 17. Global Neuropsychiatric Disorders And Treatment share by Players (Top 5) 2022(%)
  • Figure 18. BCG Matrix for key Companies
  • Figure 19. AviadoBio (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 20. AviadoBio (United Kingdom) Revenue: by Geography 2022
  • Figure 21. Universal Health Services Inc (United States) Revenue, Net Income and Gross profit
  • Figure 22. Universal Health Services Inc (United States) Revenue: by Geography 2022
  • Figure 23. Bristol-Meyer Squibb (United States) Revenue, Net Income and Gross profit
  • Figure 24. Bristol-Meyer Squibb (United States) Revenue: by Geography 2022
  • Figure 25. Wyeth (United States) Revenue, Net Income and Gross profit
  • Figure 26. Wyeth (United States) Revenue: by Geography 2022
  • Figure 27. Eli Lilly (United States) Revenue, Net Income and Gross profit
  • Figure 28. Eli Lilly (United States) Revenue: by Geography 2022
  • Figure 29. Biogen (Unites States) Revenue, Net Income and Gross profit
  • Figure 30. Biogen (Unites States) Revenue: by Geography 2022
  • Figure 31. Astrazeneca (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 32. Astrazeneca (United Kingdom) Revenue: by Geography 2022
  • Figure 33. Glaxosmithkline (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 34. Glaxosmithkline (United Kingdom) Revenue: by Geography 2022
  • Figure 35. Alto Neuroscience, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 36. Alto Neuroscience, Inc. (United States) Revenue: by Geography 2022
  • Figure 37. Global Neuropsychiatric Disorders And Treatment: by Types USD Million (2023-2028)
  • Figure 38. Global Neuropsychiatric Disorders And Treatment: by End Users USD Million (2023-2028)
  • Figure 39. Global Neuropsychiatric Disorders And Treatment: by Route of Administration USD Million (2023-2028)
  • Figure 40. Global Neuropsychiatric Disorders And Treatment: by Distribution Channel USD Million (2023-2028)
  • Figure 41. Global Neuropsychiatric Disorders And Treatment: by Treatments USD Million (2023-2028)
  • Figure 42. Global Neuropsychiatric Disorders And Treatment: by Drug Class USD Million (2023-2028)
  • Figure 43. South America Neuropsychiatric Disorders And Treatment Share (%), by Country
  • Figure 44. Asia Pacific Neuropsychiatric Disorders And Treatment Share (%), by Country
  • Figure 45. Europe Neuropsychiatric Disorders And Treatment Share (%), by Country
  • Figure 46. MEA Neuropsychiatric Disorders And Treatment Share (%), by Country
  • Figure 47. North America Neuropsychiatric Disorders And Treatment Share (%), by Country
List of companies from research coverage that are profiled in the study
  • AviadoBio (United Kingdom)
  • Universal Health Services Inc (United States)
  • Bristol-Meyer Squibb (United States)
  • Wyeth (United States)
  • Eli Lilly (United States)
  • Biogen (Unites States)
  • Astrazeneca (United Kingdom)
  • Glaxosmithkline (United Kingdom)
  • Alto Neuroscience, Inc. (United States)
Additional players considered in the study are as follows:
Johnson & Johnson (United States) , Pfizer (United States) , Otsuka Holdings Co. Ltd (Japan) , Astellas Pharma Inc. (Japan) , Boehringer ingelheim Gmbh (Germany) ,
Select User Access Type

Key Highlights of Report


Jan 2024 223 Pages 57 Tables Base Year: 2022 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Neuropsychiatric Disorders And Treatment Market Quantitative research analysis
Global Neuropsychiatric Disorders And Treatment Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as AviadoBio (United Kingdom), Universal Health Services Inc (United States), Bristol-Meyer Squibb (United States), Wyeth (United States), Eli Lilly (United States), Biogen (Unites States), Astrazeneca (United Kingdom), Glaxosmithkline (United Kingdom) and Alto Neuroscience, Inc. (United States) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Increasing use of digital tools, mobile applications, and telehealth for assessment, monitoring, and intervention in neuropsychiatric disorders " is seen as one of major influencing trends for Neuropsychiatric Disorders And Treatment Market during projected period 2022-2028.
The Neuropsychiatric Disorders And Treatment market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.
Analysts at AMA estimates Neuropsychiatric Disorders And Treatment Market to reach USD166300.0 Million by 2028.

Know More About Global Neuropsychiatric Disorders And Treatment Market Report?

Have a Query? Click Here

Other Related Reports

Sepsis and Septic Shock Comprehensive Study by Type (Automated Diagnostics, Conventional Diagnostics), By End User (Hospitals, Pathology Center, Laboratories, Research Organization, Others), By Techn...
$ 3800
Upper-limb Robotic Neurorehabilitation Comprehensive Study by Type (Exoskeletons, End-effector Devices, Robotic Arms, Electrical Stimulation Devices, VR Systems, Others), By End User (Hospitals & Cli...
$ 3800
TMJ Disorders Comprehensive Study by Type (Muscular, Structural, Acute), Treatment (-Nonsurgical Treatments, Mouth Guards, Physical Therapy, Trigger Point Injections, Others, -Surgery, Arthrocentesis...
$ 3800
Hallux Rigidus Comprehensive Study by Treatment (-Non-Surgical Treatment, Shoe Modification, Orthotic Devices, Medications, Injection Therapy, Physical Therapy, -Surgical Treatment, Bone Spur Removal...
$ 3800
Teledermatology Comprehensive Study by Application (Direct consultations, Specialist referral, Online patient triage, Virtual prescription renewals, Patient follow-up care), Type (Synchronous, Asynch...
$ 3800
Retinal Detachment- Comprehensive Study by Type (Rhegmatogenous, Tractional, Exudative), Treatment Type (Surgical Others, Laser Therapy, Cryopexy, Others), End User (Hospitals, Speciality centre, Cl...
$ 3800